Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented as Platform Presentation

Aerosurf Utilizing Chrysalis Aerosol-Generator Technology Demonstrates Optimal Functional Activity

WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.

Phase 2 Clinical Trial of Surfaxin(r) for the Prevention and Treatment of BPD

Carl Bose, MD, Director of Neonatology and Professor of Pediatrics at University of North Carolina and Chairman of the Discovery BPD Clinical Study Steering Committee, presented an overview of key trial data. These data suggest that Surfaxin, when administered beyond the standard acute Respiratory Distress Syndrome (RDS) treatment period, may represent a novel therapeutic option for infants at risk for developing BPD. BPD is a chronic, debilitating lung disease affecting premature infants who survive treatment for RDS. Presently, there are no approved pharmaceutical therapies for BPD.

Surfaxin was shown to be generally safe and well-tolerated. Top-line results demonstrated that infants treated with up to five incremental standard doses of Surfaxin experienced:

* a lower incidence of death or BPD,

* a higher survival rate thr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 15, 2011 XTIO2 INC . ... the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM ... XTI™  Nano-Facemask . It is the world,s most ... transmitted via air and contact surfaces. The unique nanocoating ...
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading ... disorders, today announced that researchers at Samuel Merritt University ... Grant to study the effects of wearing a strategically ... with MS. This grant comes after ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... tool developed at the University of Utah (U of ... in three separate cases, U of U researchers and ... The American Journal of Human Genetics . The software, ... illnesses and unknown gene mutations by analyzing the exomes, ... genes are made, in individual patients and small families. ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... of Buffalo had said that postmenopausal women would have lesser ... periodontal disease at bay. Their research was published in the ... studied 106 postmenopausal women had found that in an average ... one tooth. Their research says that alveolar bone loss is ...
... A nine-year-old boy in a West Bengal town is said to ... his Rip Van Winkle act. // ,Reports Saturday said Arup ... playful boy of eight until 11 months ago when he suddenly ... and recite very well, can now only be half awakened for ...
... Z-Trim fat replacer at a recent show //in New Orleans. ... variety of products without altering the food's original taste. ... Z-Trim fat replacer at a recent show in New Orleans. ... symposia and 14,000 attendees. , ,According to the manufacturers, ...
... small packages. So are the twin electroneedles, which is ... heart attack episodes. The two arrays of micron-sized ... ,Good thing come in small packages. So are ... also said to benefit high-risk cardiac patients by confirming ...
... remains one of the significant health problems to be ... faceted approach. A protein-based diet could help in improving ... shows that consuming a protein hydrolysate and amino acid ... diabetics, and could therefore help individuals control their blood ...
... couples who smoke according to a new study// which has ... than cigarette-smoking women with non-smoking spouses. ,The study recorded ... stroke and ischemic stroke (a stroke caused by a blood ... of women. The relative risk of total stroke was 5.7 ...
Cached Medicine News:Health News:New Insight In Periodontal Disease In Postmenopausal Women 2Health News:New Oat And Soy-Based Fat Replacer Launched 2Health News:Diabetes and heart attack diagnosis now made simple with twin magic 2Health News:Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: